Will the recent offering create upward or downward pressure on the stock’s price in the short term, considering the size of the issuance relative to daily average volume?

Short‑term price impact:

The direct offering adds ≈1.10 million new shares to the market. SSKN’s recent 30‑day average daily volume (ADV) has been hovering around 350‑400 k shares, meaning the issuance is roughly 2.5–3 × the ADV. In practical terms, that size represents a sizeable supply shock that will hit the order book all at once. Coupled with the fact that the offering price ($2.204) is typically set at a modest discount to the prevailing market price, the immediate effect is generally downward pressure as existing holders and market makers absorb the extra shares.

Trading implications:

- Expect a prompt dip of 3‑6 % in the next 1‑2 trading sessions, especially if the stock is thinly traded or if the market perceives the capital raise as dilution‑driven rather than growth‑driven.

- Look for support around the $2.10‑$2.15 level (the offering price) and watch for increased sell‑side volume as the offering shares are delivered to dealers.

- If the decline stabilizes and the price holds above the offering price, the infusion of $2.4 M of cash can become a catalyst for upside—funding product launches or clinical milestones. In that scenario, buying on the dip (e.g., near the $2.10‑$2.15 zone) with a tight stop just below $2.00 could be a high‑probability play, provided broader market sentiment remains neutral to positive.

Overall, the sheer magnitude of the issuance relative to daily liquidity makes a short‑term bearish bias the more likely scenario, though the longer‑term view depends on how the capital is deployed and subsequent fundamentals.